Considering the context-dependent activity of METTL5, future drug development should prioritize stratification of METTL5-dependent tumor subtypes, leveraging CRISPR gene dependency data, compound sensitivity profiles, and single-cell transcriptomics to enable precision targeting. Here, METTL5 is linked to neoplasm.